| Literature DB >> 35031663 |
Qing Gu1, Jian Meng1, Xue Hu1, Jun Ge1, Sui Jun Wang2, Xing Zhen Liu3.
Abstract
The vital role of insulin resistance (IR) in the pathogenesis of isolated systolic hypertension (ISH) has been expounded at the theoretical level. However, research on the correlation between some specific IR indicators and ISH is still rare, especially at different glycemic statuses. We conducted this study to explore the association between three IR indicators and ISH among young and middle-aged adults with normal fasting plasma glucose (NFG). This large cross-sectional study included 8246 young and middle-aged men with NFG and diastolic blood pressure < 90 mmHg. The homeostasis model assessment for IR (HOMA-IR) index, triglyceride glucose (TyG) index, and the metabolic score for IR (METS-IR) were calculated with the corresponding formula. The proportions of ISH among young and middle-aged men were 6.7% and 4.4%, respectively. After fully adjusting, only HOMA-IR rather than TyG and METS-IR was significantly associated with ISH. Moreover, fully adjusted smooth curve fitting showed that the association between HOMA-IR and ISH were approximately linear in both two age groups (P for non-linearity were 0.047 and 0.430 in young and middle-aged men, respectively). Among young and middle-aged men with NFG, using HOMA-IR instead of noninsulin-dependent IR indicators may have advantages in the hierarchical management of ISH. Further longitudinal research may be needed to determine their potential causal relationship.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35031663 PMCID: PMC8760306 DOI: 10.1038/s41598-021-04763-x
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
The basic clinical characteristics of young and middle-aged men with normal fasting glucose by blood pressure status.
| Characteristics | Young men | Middle-aged men | ||||
|---|---|---|---|---|---|---|
| Non-hypertension | ISH | Non-hypertension | ISH | |||
| No., n (%) | 2252 | 163 (6.7) | – | 5573 | 258 (4.4) | – |
| Age (year) | 29.8 ± 3.8 | 29.9 ± 3.7 | 0.739 | 42.9 ± 4.6 | 42.5 ± 4.8 | 0.253 |
| Smoking (%) | 21.6% | 19.3% | 0.553 | 34.4% | 26.7% | 0.029 |
| Drinking (%) | 15.9% | 17.6% | 0.609 | 25.8% | 29.3% | 0.283 |
| NAFL (%) | 17.5% | 20.8% | 0.021 | 20.1% | 24.2% | 0.036 |
| BMI (kg/m2) | 23.5 ± 3.3 | 25.7 ± 4.4 | < 0.001 | 24.0 ± 2.9 | 25.5 ± 3.2 | < 0.001 |
| WC (cm) | 80.2 ± 8.7 | 85.2 ± 11.5 | < 0.001 | 82.5 ± 7.5 | 85.8 ± 8.5 | < 0.001 |
| WHR | 0.84 ± 0.05 | 0.86 ± 0.07 | < 0.001 | 0.87 ± 0.05 | 0.89 ± 0.05 | < 0.001 |
| WHtR | 0.46 ± 0.05 | 0.49 ± 0.07 | < 0.001 | 0.48 ± 0.04 | 0.50 ± 0.05 | < 0.001 |
| SBP (mmHg) | 120.2 ± 11.1 | 144.7 ± 5.1 | < 0.001 | 118.3 ± 11.1 | 145.9 ± 5.9 | < 0.001 |
| DBP (mmHg) | 72.1 ± 8.1 | 81.3 ± 5.6 | < 0.001 | 74.7 ± 8.0 | 83.8 ± 4.8 | < 0.001 |
| HR (beats/min) | 79.1 ± 12.2 | 85.3 ± 12.9 | < 0.001 | 76.2 ± 11.0 | 82.2 ± 12.3 | < 0.001 |
| FPG (mmol/L) | 5.17 ± 0.29 | 5.21 ± 0.25 | < 0.001 | 5.20 ± 0.28 | 5.27 ± 0.29 | 0.001 |
| UA (μmol/L) | 389.9 ± 75.5 | 398.9 ± 78.4 | 0.143 | 381.2 ± 72.7 | 393.7 ± 79.3 | 0.007 |
| TC (mmol/L) | 4.50 ± 0.80 | 4.68 ± 0.78 | 0.006 | 4.77 ± 0.85 | 4.79 ± 0.96 | 0.651 |
| TG (mmol/L) | 1.30 ± 0.86 | 1.53 ± 1.12 | 0.002 | 1.71 ± 1.42 | 1.85 ± 1.21 | 0.113 |
| HDLc (mmol/L) | 1.42 ± 0.28 | 1.39 ± 0.33 | 0.141 | 1.39 ± 0.29 | 1.34 ± 0.27 | 0.006 |
| LDLc (mmol/L) | 2.47 ± 0.68 | 2.56 ± 0.70 | 0.122 | 2.64 ± 0.71 | 2.67 ± 0.79 | 0.520 |
| ALT (U/L) | 31.4 ± 25.3 | 36.1 ± 26.5 | 0.025 | 31.0 ± 25.2 | 36.4 ± 25.2 | 0.001 |
| AST (U/L) | 22.3 ± 10.5 | 23.9 ± 11.7 | 0.062 | 22.5 ± 11.7 | 24.1 ± 9.4 | 0.029 |
| ALP (U/L) | 67.7 ± 18.1 | 67.0 ± 16.9 | 0.661 | 67.5 ± 16.5 | 69.0 ± 16.7 | 0.168 |
| GGT (U/L) | 30.2 ± 23.4 | 35.4 ± 33.2 | 0.009 | 38.7 ± 36.2 | 46.1 ± 39.0 | 0.001 |
| Insulin (μU/mL) | 9.83 ± 5.95 | 12.57 ± 8.00 | < 0.001 | 9.36 ± 5.14 | 11.73 ± 6.35 | < 0.001 |
| HOMA-IR | 2.27 ± 1.38 | 2.92 ± 1.91 | < 0.001 | 2.18 ± 1.22 | 2.75 ± 1.48 | < 0.001 |
| TyG | 8.44 ± 0.51 | 8.56 ± 0.65 | 0.007 | 8.69 ± 0.55 | 8.79 ± 0.56 | 0.003 |
| METS-IR | 33.7 ± 6.3 | 37.6 ± 8.6 | < 0.001 | 35.3 ± 6.0 | 38.1 ± 6.7 | < 0.001 |
NAFL nonalcoholic fatty liver, BMI body mass index, WC waist circumference, WHR waist to hip ratio, WHtR waist to height ratio, SBP systolic blood pressure, DBP diastolic blood pressure, HR heart rate, FPG fasting plasma glucose, UA plasma uric acid, TC total cholesterol, TG triglyceride, HDLc high-density lipoprotein cholesterol, LDLc low-density lipoprotein cholesterol, ALT alanine aminotransferase, AST aspartate aminotransferase, ALP alkaline phosphatase, GGT gamma glutamyltranspeptidase, HOMA-IR homeostasis model assessment for IR index, TyG triglyceride glucose index, METS-IR metabolic score for IR.
Figure 1The correlation matrix between systolic blood pressure and insulin resistance indicators. SBP systolic blood pressure, IR insulin resistance, HOMA-IR homeostasis model assessment for IR index, TyG triglyceride glucose index, METS-IR metabolic score for IR.
Figure 2The proportion of ISH by categories of the tertiles of insulin resistance indicators. ISH isolated systolic hypertension, HOMA-IR homeostasis model assessment for IR index, TyG triglyceride glucose index, METS-IR metabolic score for IR, T tertiles.
Logistic regression analysis for the association of three IR indicators with ISH.
| Model 1 | Model 2 | Model 3 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| OR | LLCI | ULCI | OR | LLCI | ULCI | OR | LLCI | ULCI | |
| T2 (1.57–2.54) | 1.143 | 0.726 | 1.798 | 0.953 | 0.591 | 1.536 | 1.201 | 0.691 | 2.090 |
| T3 (> 2.54) | 2.418** | 1.621 | 3.607 | 1.747* | 1.082 | 2.819 | 2.369** | 1.348 | 4.163 |
| T2 (8.17–8.64) | 1.193 | 0.789 | 1.804 | 0.946 | 0.609 | 1.470 | 0.894 | 0.540 | 1.482 |
| T3 (> 8.64) | 1.572* | 1.061 | 2.331 | 0.887 | 0.545 | 1.446 | 0.781 | 0.442 | 1.381 |
| T2 (30.68–36.18) | 1.303 | 0.828 | 2.049 | 1.002 | 0.605 | 1.659 | 0.945 | 0.533 | 1.675 |
| T3 (> 36.18) | 2.529** | 1.682 | 3.803 | 1.316 | 0.682 | 2.536 | 1.123 | 0.523 | 2.413 |
| T2 (1.54–2.45) | 1.355 | 0.944 | 1.945 | 1.104 | 0.756 | 1.612 | 1.081 | 0.701 | 1.667 |
| T3 (> 2.45) | 2.643** | 1.910 | 3.656 | 1.788** | 1.228 | 2.605 | 1.757* | 1.143 | 2.700 |
| T2 (8.41–8.88) | 1.343 | 0.967 | 1.865 | 0.950 | 0.669 | 1.348 | 0.753 | 0.502 | 1.131 |
| T3 (> 8.88) | 1.686** | 1.231 | 2.311 | 0.913 | 0.626 | 1.333 | 0.800 | 0.517 | 1.237 |
| T2 (32.6–37.8) | 1.747** | 1.221 | 2.499 | 1.286 | 0.853 | 1.938 | 1.517 | 0.942 | 2.442 |
| T3 (> 37.8) | 2.659** | 1.899 | 3.723 | 1.491 | 0.901 | 2.466 | 1.746 | 0.971 | 3.141 |
Model 1 was crude.
Model 2 was adjusted for abdominal obesity and non-alcoholic fatty liver.
Model 3 was adjusted for abdominal obesity, non-alcoholic fatty liver, hyperuricemia, smoking, and drinking.
OR Odds ratio, LLCI and ULCI lower level and upper level of 95% confidence interval, T tertile; the first tertile was used as the reference category, HOMA-IR homeostasis model assessment for IR index, TyG triglyceride glucose index, METS-IR metabolic score for IR; **< 0.01; *< 0.05.
Figure 3Fully adjusted association between insulin resistance indicators and ISH using cubic smoothing splines. OR Odds ratios, ISH isolated systolic hypertension, HOMA-IR homeostasis model assessment for IR index, TyG triglyceride glucose index, METS-IR metabolic score for IR; adjusted for abdominal obesity, non-alcoholic fatty liver, hyperuricemia, smoking, and drinking.